# Zantac (ranitidine) cancer litigation explained

> How the recalled heartburn medication produced NDMA, a probable human carcinogen.

**Canonical URL:** https://drugsmonitor.com/guides/zantac-cancer-litigation
**Last updated:** 2026-06-11

Zantac (ranitidine) and its generic versions were widely used for heartburn and acid reflux. In 2019, independent testing revealed that ranitidine can form NDMA (N-nitrosodimethylamine), a probable human carcinogen, at levels exceeding FDA acceptable limits.

The FDA requested a market withdrawal in 2020, and the manufacturer removed all ranitidine products. Plaintiffs allege that ranitidine use caused various cancers including bladder, liver, stomach, pancreatic, and esophageal cancer.

The litigation has been consolidated into MDL 2924. If you took Zantac or generic ranitidine and were diagnosed with cancer, consult an attorney to evaluate your claim statute of limitations.

---

*Educational guide from DrugsMonitor.com. Not legal advice.*